Shamburg News · 8-K/A filed Nov 16, 2026, 4:15 PM EST

Cumberland Pharmaceuticals Plans NDA Filing for Ifetroban in Duchenne Cardiomyopathy

CPIX · CUMBERLAND PHARMACEUTICALS INC

  • Other event
  • Reg FD disclosure
  • Materiality: medium

Cumberland Pharmaceuticals announced plans to submit a New Drug Application to the FDA for ifetroban as a potential treatment for cardiomyopathy associated with Duchenne muscular dystrophy. The FDA granted the company's request for a rolling submission of the NDA following a pre-NDA meeting. The company cited a 5.4% absolute improvement in left ventricular ejection fraction in the Phase 2 FIGHT DMD trial versus a control group. The filing was furnished as Exhibit 99.1 under Item 9.01 and the press release is dated October 26, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K/A, Item 9.01, accession 0001087294-26-000087.

Written from the filing by Shamburg Markets. Figures are as reported by the company.